Almirall LBTSF Stock
Almirall Price Chart
Almirall LBTSF Financial and Trading Overview
| Almirall stock price | 9.01 USD |
| Previous Close | 9.68 USD |
| Open | 9.68 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 9.68 - 9.68 USD |
| 52 Week Range | 9.28 - 10.4 USD |
| Volume | 106 USD |
| Avg. Volume | 396 USD |
| Market Cap | 1.79B USD |
| Beta (5Y Monthly) | 0.408812 |
| PE Ratio (TTM) | 56.941177 |
| EPS (TTM) | 0.06 USD |
| Forward Dividend & Yield | 0.2 (2.05%) |
| Ex-Dividend Date | May 12, 2023 |
| 1y Target Est | N/A |
LBTSF Valuation Measures
| Enterprise Value | 3.18B USD |
| Trailing P/E | 56.941177 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.0652204 |
| Price/Book (mrq) | 2.2840965 |
| Enterprise Value/Revenue | 3.663 |
| Enterprise Value/EBITDA | 17.517 |
Trading Information
Almirall Stock Price History
| Beta (5Y Monthly) | 0.408812 |
| 52-Week Change | -6.92% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10.4 USD |
| 52 Week Low | 9.28 USD |
| 50-Day Moving Average | 9.68 USD |
| 200-Day Moving Average | 9.59 USD |
LBTSF Share Statistics
| Avg. Volume (3 month) | 396 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 184.92M |
| Float | 125.82M |
| Short Ratio | N/A |
| % Held by Insiders | 59.67% |
| % Held by Institutions | 15.32% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 1.1625 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -0.97% |
| Operating Margin (ttm) | 6.71% |
| Gross Margin | 78.16% |
| EBITDA Margin | 20.91% |
Management Effectiveness
| Return on Assets (ttm) | 1.71% |
| Return on Equity (ttm) | -0.63% |
Income Statement
| Revenue (ttm) | 866.75M USD |
| Revenue Per Share (ttm) | 4.03 USD |
| Quarterly Revenue Growth (yoy) | 1.50% |
| Gross Profit (ttm) | 681.46M USD |
| EBITDA | 181.25M USD |
| Net Income Avi to Common (ttm) | -8419000 USD |
| Diluted EPS (ttm) | 0.17 |
| Quarterly Earnings Growth (yoy) | -62.29% |
Balance Sheet
| Total Cash (mrq) | 197.8M USD |
| Total Cash Per Share (mrq) | 0.64 USD |
| Total Debt (mrq) | 360.4M USD |
| Total Debt/Equity (mrq) | 27.3 USD |
| Current Ratio (mrq) | 2.191 |
| Book Value Per Share (mrq) | 4.238 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 153.7M USD |
| Levered Free Cash Flow (ttm) | 46.4M USD |
Profile of Almirall
| Country | United States |
| State | N/A |
| City | Barcelona |
| Address | Ronda Del General Miter, 151 |
| ZIP | 08022 |
| Phone | 34 93 291 30 00 |
| Website | https://www.almirall.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 1814 |
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Q&A For Almirall Stock
What is a current LBTSF stock price?
Almirall LBTSF stock price today per share is 9.01 USD.
How to purchase Almirall stock?
You can buy LBTSF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Almirall?
The stock symbol or ticker of Almirall is LBTSF.
Which industry does the Almirall company belong to?
The Almirall industry is Drug Manufacturers-Specialty & Generic.
How many shares does Almirall have in circulation?
The max supply of Almirall shares is 260.27M.
What is Almirall Price to Earnings Ratio (PE Ratio)?
Almirall PE Ratio is 150.16667000 now.
What was Almirall earnings per share over the trailing 12 months (TTM)?
Almirall EPS is 0.06 USD over the trailing 12 months.
Which sector does the Almirall company belong to?
The Almirall sector is Healthcare.